Market Size-
North America Viral Vector And Plasmid DNA Manufacturing Market size is expected to reach USD XX.X billion by 2033, with growth at a CAGR of 25% during the forecast period 2026-2033.
The increasing number of approvals for novel gene therapies by regulatory authorities is also a major factor contributing to the market's growth.
There is an increase in the contract manufacturing business launch for viral vectors and plasmid DNA manufacturing.The company would establish additional smaller-scale reactors (60-300 L, 6-30 L) with feasibility runs and start a small-volume production service.
Market Dynamics
The rising number of gene therapy patients is expected to drive the market growth
An increasing number of patients opting for gene therapy to treat diseases such as cancer, cystic fibrosis, heart disease, diabetes, hemophilia, and AIDS is one of the major factors driving the growth of the market over the forecast period. The demand for plasmid DNA is growing owing to the increase in gene therapy development. Plasmid DNA is a prerequisite for producing AAV (adeno-associated virus), lentivirus, and other viral vector platforms. Adeno-associated AAV2 vectors carrying the therapeutic gene (RPE65) intra-retinal injection help in improving the vision of individuals suffering from Liber's Congenital Amaurosis. Gene therapy with viral vectors provides a complete cure to patients affected with genetic disorders and other life-threatening disorders, rather than easing symptoms with other treatments. The successful launch of viral vector gene therapies and a robust pipeline of such therapies are the key factors contributing to the growth of the global viral vector manufacturing market.
Increasing collaboration among companies and organizations for the development of viral vectors
There is an increase in collaborations among companies and several organizations, research institutes, and non-profit organizations to develop and produce viral vectors and plasmid DNA.The partnership will allow the parties to utilize Dyno's CapsidMap artificial intelligence platform along with Novartis's expertise in gene therapy development and global commercialization to deliver innovative gene therapies to patients with serious diseases of the eye.
Key Drivers
The market is driven by the increasing demand for viral vectors and plasmid DNA manufacturing for developing DNA vaccines, gene therapy, immunotherapy, and others. There is growing usage of viral vectors & plasmid DNA due to their advantages such as high transfection efficiency, effective gene delivery, and stable gene expression. There is a rise in the number of clinical studies for examining the efficacy and safety of viral vectors. In addition, increase in the launch of the contract manufacturing business for viral vectors and plasmid DNA manufacturing.
Growing demand for vaccines drives the vaccinology segment
Based on application, the vaccinology segment is estimated to grow at the highest CAGR of 21.5% during the forecast period (2026-2033). Viral vector-based vaccines differ from most conventional vaccines in that they don’t contain antigens but rather use the body’s cells to produce them. Viral vector-based vaccines can enhance immunogenicity without an adjuvant and induce a robust cytotoxic T lymphocyte (CTL) response to eliminate virus-infected cells.
North America Viral Vector And Plasmid DNA Manufacturing Market Scope
| Metrics | Details |
| Market CAGR | 25% |
| Segments Covered | By Product Type, By Application, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
For More Insights Request Free Sample
North America Viral Vector And Plasmid Dna Manufacturing Market Competition Landscape
- Detailed profiles of providers of viral vector and plasmid DNA manufacturing have been provided in the report to evaluate their financials, key product offerings, recent developments, and strategies
- Some of the key players operating in the North America Viral Vector And Plasmid DNA Manufacturing market are Lonza, Merck, Oxford BioMedica, CGT Catapult, Cobra Biologics, UniQure, Sanofi, FUJIFILM Diosynth Biotechnologies, Cobra Biologics, Thermo Fisher Scientific, Inc. and Spark Therapeutics.
Recent Development-
- March 2026: Thermo Fisher Scientific expanded its viral vector manufacturing capacity in Massachusetts, adding advanced GMP suites dedicated to AAV and lentiviral vector production to meet rising demand from gene therapy developers across North America.
- March 2026: WuXi Advanced Therapies expanded its global plasmid DNA and viral vector manufacturing network, indirectly supporting North American biotech firms through cross-border CDMO partnerships and technology transfer programs.
- January 2026: Samsung Biologics announced strategic expansion into cell and gene therapy manufacturing, including viral vector capabilities, intensifying global competition for North American CDMOs.
- January 2026: Catalent announced continued investment in its Maryland cell and gene therapy facility, enhancing plasmid DNA manufacturing capabilities with high-yield fermentation technologies to support clinical and commercial-stage therapies.
- November 2025: Pfizer strengthened its internal gene therapy manufacturing network by upgrading viral vector production infrastructure, focusing on scalable AAV platforms for rare disease pipelines.
